Immuno-Oncology
Key updates on CAR-T therapy for multiple myeloma
The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing…
Date: 2nd August 2021
The Lymphoma Sessions: highlights from EHA and ICML 2021
In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD,…
Date: 30th July 2021
The CLL Sessions: highlights from EHA and ICML 2021
In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University…
Date: 27th July 2021
iwNHL 2021: immunotherapy and the microenvironment
Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma….
Date: 23rd July 2021
The Myeloma Sessions: key highlights from EHA and ASCO 2021
The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…
Date: 21st July 2021
The MDS Sessions: highlights from ASCO/EHA 2021
Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not…
Date: 8th July 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…
Date: 8th July 2021
The AML Sessions: Highlights from ASCO/EHA 2021
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…
Date: 7th July 2021
Key updates on CAR-T therapy for ALL
There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases)….
Date: 5th July 2021
Latest updates on CAR-T therapy for CLL
Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…
Date: 16th June 2021
The Myeloma Sessions: post-COMy 2021 roundtable
Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…
Date: 3rd June 2021
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…
Date: 28th May 2021
